Skip to main content
Defiance International

CerebrolysinTM efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.

In vivo/preclinical record. BMC neuroscience, 2014.

  • Animal
  • 2014

Authorship

Exact sentences from the abstract. No machine-written text is on this page. No person reviewed it.

Source: the abstract of PMID 25047000. Checked Verification: Evidence verified by machine against declared source

This study and its findings belong to the authors cited. Defiance International, a supplier of chemical sequences for research use, keeps this record and makes no claim from its findings.

Verify a lot

Evidence verified by machine against declared source

Open declared source

Key facts

Design
Not reported
System
Animal
Scale
A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.
Comparator
Present
Journal
BMC neuroscience
Year
2014
PMID
25047000
Verification
Evidence verified by machine against declared source The stored extraction was checked against its declared source. Public summary availability is separate. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.
Full-text availability
Abstract only

Technical summary

Research question

For this purpose we sought to investigate the effects of CBL in a tg model of tauopathy.

Participants or experimental system

Accordingly, double tg mice expressing mutant Tau under the mThy-1 promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically.

Study scale

A total of 24 Tau/GSK3β tg mice (3 month (m) old; n = 12 CBL treated and n = 12 saline) and 24 non tg mice (3 m old; n = 12 CBL treated and n = 12 saline) were utilized.

Intervention or exposure

Animals were treated beginning at 3 months of age for 3 months, because at the earlier age group the Tau pathology was subtler, becoming progressively worse at 6 and 12 months of age.

Comparator

By immunoblot, levels of t-Tau were elevated in the Tau/GSK3β bigenic mice compared to the non-tg, no effects of CBL administration on t-Tau were observed (Figure 3A-D).

Outcomes examined

Non-tg and bigenic mice were treated for 3 months (beginning at 3 months of age) with CBL and brains were analyzed with p-tau antibodies.

Key findings

CBL treatment reduced the levels of Tau phosphorylation in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/GSK3β double tg mice.

Not reported in the declared source: Methods, Study design.

Limitations and uncertainty

Not reported in the declared source.

Cite

Cite the study

CerebrolysinTM efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.
Rockenstein E, Ubhi K, Trejo M et al. BMC neuroscience. 2014. PMID 25047000

The study and its abstract belong to their authors and publisher. Cite them for anything the study found.

Report an error

If a sentence on this record does not match the abstract, tell us which one. A report starts an automatic re-check by machine. No person reads the record first.

The form takes a sentence and your note. It asks for no name and no address, and we store neither. Do not put personal details in the note.

The report form runs in the interactive page. Open this record with scripts enabled to send a report.

Corrections on this record

No correction has been recorded for this record.

Method sheet

No machine-drafted summary is published on this record. Any section shown is the abstract’s own sentence, printed as issued.